Browse Penn-owned technologies available for licensing.
Dr. Kelly and his colleagues developed a small molecule therapeutic that inhibits intracellular lipid accumulation in the liver and skeletal muscle while also reducing insulin resistance. This effect occurs by inhibiting the transcription factor MondoA.
Inhibition of MondoA has the potential reduce both the end-organ lipid toxicity and insulin resistance driven by obesity and type 2 diabetes. It could prevent intracellular lipid accumulation and enhance insulin signaling.